Notably, PHGDH inhibitors effectively suppress the growth of IDH2-overexpressing breast tumors in pre-clinical models, indicating that targeting PHGDH could be a promising approach for TNBC with IDH2 overexpression (Barnabas et al., 2021). Here, PHGDH is linked to breast neoplasm.